HACKENSACK, N.J., Dec. 14, 2015 /PRNewswire/ -- Champions Oncology, Inc. (CSBR), a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that it signed an agreement with a top 20 global pharmaceutical company to develop a novel process for establishing hematology models. The initial agreement will provide near-term revenue for the Company, as well as result in a longer-term revenue growth stream.
This deal includes feasibility studies of an innovative process to establish tumor models of acute myelogenous leukemia (AML) using peripheral blood. Neal Goodwin, Vice President, Corporate Research Development at Champions Oncology, said, "AML is a clinically and molecularly heterogeneous disease. Outcomes are poor and there is significant unmet need. Historically, AML has been pre-clinically modeled utilizing bone marrow aspirates, which has significant implications for the patient, as well as logistic challenges, when creating an in vivo testing platform that is closely coordinated with a clinical trial. Expanding on the previously-established techniques to build AML tumor models using peripheral blood versus bone marrow aspirates enables real-time modeling, which will dramatically change the paradigm of conducting co-clinical studies in this important therapeutic area."
In making the announcement, Joel Ackerman, CEO at Champions Oncology, explained, "We are very pleased to announce this deal as it is truly representative of our pioneering philosophy. With this agreement, we build the breadth of our platform by expanding the utility of the Champions TumorGraft® platform for the study of hematological malignancies. This sets the foundation for Champions to test novel therapeutics in AML and to improve the success rate translating the sponsor's drug candidates into the clinical setting. In addition, the considerable scope reflects the collaborative nature of our growing partnership with pharmaceutical and biotech companies, and is indicative of the long-term relationships we strive to create."
About Champions Oncology
Champions Oncology, Inc. is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The company's technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune deficient mice followed by propagation of the resulting engraftments, or Champions TumorGrafts, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The Company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. TumorGrafts are procured through agreements with a number of institutions in the U.S. and overseas as well as through Champions' Personalized Oncology Solutions business. For more information, please visit www.championsoncology.com.
SOURCE Champions Oncology, Inc.